Abstract

CD44 adhesion molecules are expressed in many breast cancer cells and have been demonstrated to play a key role in regulating malignant phenotypes such as growth, migration, and invasion. CD44 is an integral transmembrane protein encoded by a single 20-exon gene. The diversity of the biological functions of CD44 is the result of the various splicing variants of these exons. Previous studies suggest that exon v10 of CD44 plays a key role in promoting cancer invasion and metastasis, however, the molecular mechanisms are not clear. Given the fact that exon v10 is in the ectodomain of CD44, we hypothesized that CD44 forms a molecular complex with other cell surface molecules through exon v10 in order to promote migration of breast cancer cells. In order to test this hypothesis, we selected DNA aptamers that specifically bound to CD44 exon v10 using Systematic Evolution of Ligands by Exponential Enrichment (SELEX). We selected aptamers that inhibited migration of breast cancer cells. Co-immunoprecipitation studies demonstrated that EphA2 was co-precipitated with CD44. Pull-down studies demonstrated that recombinant CD44 exon v10 bound to EphA2 and more importantly aptamers that inhibited migration also prevented the binding of EphA2 to exon v10. These results suggest that CD44 forms a molecular complex with EphA2 on the breast cancer cell surface and this complex plays a key role in enhancing breast cancer migration. These results provide insight not only for characterizing mechanisms of breast cancer migration but also for developing target-specific therapy for breast cancers and possibly other cancer types expressing CD44 exon v10.

Highlights

  • Enhanced migration into the surrounding tissues is one of the hallmarks of the malignancy of tumor cells

  • Given the fact that EphA2 plays a key role in promoting tumor invasion and metastasis, our results suggest a novel model of a molecular complex consisting of CD44 and EphA2 that facilitates TN breast cancer progression

  • Previous studies demonstrated that antibodies against CD44 exon v10 inhibited leukocytes migration to inflammation sites and homing to bone marrow, suggesting that this exon plays a key role in regulating the processes of cell adhesion and migration [22,23,24]

Read more

Summary

Introduction

Enhanced migration into the surrounding tissues is one of the hallmarks of the malignancy of tumor cells. Aptamers are evolved by an iterative selection method called SELEX (systematic evolution of ligands by exponential enrichment) to recognize and tightly bind their targets by means of well-defined complementary three-dimensional structures [1,2]. They have been developed against intracellular and extracellular molecules expressed in cancer cells and demonstrated to attenuate the biological functions of their target molecules [3,4,5,6,7,8,9,10]. Phase II trial of AS1411, aptamer targeting nucleolin, demonstrated its efficacy in renal cell carcinoma patients [17], suggesting that DNA aptamers represent a novel therapeutic strategy for cancer therapy

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call